Efficacy of Bromfenac Sodium Ophthalmic Solution for Treatment of Dry Eye Disease

被引:12
|
作者
Fujishima, Hiroshi [1 ]
Fuseya, Miki [2 ]
Ogata, Masarou [2 ]
Murat, Dogru [3 ]
机构
[1] Tsurumi Univ, Sch Dent Med, Dept Ophthalmol, Kanagawa, Japan
[2] Tokyo Saiseikai Cent Hosp, Dept Ophthalmol, Tokyo, Japan
[3] Keio Univ, Sch Med, J&J Ocular Surface & Visual Opt Dept, Tokyo, Japan
来源
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY | 2015年 / 4卷 / 01期
关键词
bromfenac sodium; dry eye disease; artificial tears; combined therapy;
D O I
10.1097/APO.0000000000000032
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the efficacy of bromfenac sodium ophthalmic solution (BF) in patients with dry eye disease (DED) inadequately controlled by monotherapy with artificial tears (ATs). Design: An investigator-oriented trialwith a single-arm, nonrandomized, open-label design. Methods: Twenty-six patients, who showed no symptomatic improvement of DED after 1 month of AT treatment, were enrolled. Bromfenac sodium ophthalmic solution was administered adjunctively with AT for 1 month. The BF treatment was then discontinued, and AT treatment alone was continued for 3 months. The signs and symptoms were evaluated at the beginning of BF treatment (Pre), at the end of the combined BF and AT treatment (BF1M), and at 1 and 3 months after discontinuation of BF treatment (Po1M and Po3M, respectively). Results: The dryness scores at BF1M were significantly improved compared with Pre (P < 0.001) and significantly superior to Po3M (P < 0.001). No significant changes in the Schirmer scores were observed throughout the treatment period. The tear film breakup time was significantly improved at BF1M (4.4 (sic) 2.3 seconds) compared with Pre (2.8 (sic) 1.8 seconds; P < 0.001). Superficial punctate keratopathy showed significant improvements in the total score of area and density at BF1M compared with Pre (P < 0.001). However, these parameters had significantly worsened at Po3M compared with BF1M. No adverse events were observed. Conclusions: Bromfenac sodium ophthalmic solution has improved the dryness of the eye and signs of DED through its anti-inflammatory effects. Nonsteroidal anti-inflammatory drugs were suitable as anti-inflammatory ophthalmic solutions for patients with DED.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 50 条
  • [21] Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease
    Keating, Gillian M.
    DRUGS, 2017, 77 (02) : 201 - 208
  • [22] Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease
    Gillian M. Keating
    Drugs, 2017, 77 : 201 - 208
  • [23] Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
    Patel, Jay
    Franko, John
    AMERICAN FAMILY PHYSICIAN, 2018, 98 (02) : 119 - 120
  • [24] Performance and Safety of a Sodium Hyaluronate, Xanthan Gum, and Osmoprotectants Ophthalmic Solution in the Treatment of Dry Eye Disease: An Observational Clinical Investigation
    Senosiain, Mercedes Molero
    Burgos-Blasco, Barbara
    Perez-Garcia, Pilar
    Sanchez-Ventosa, Alvaro
    Villalba-Gonzalez, Marta
    Perez, Maria Dolores Lopez
    Diaz, Jose Carlos
    Diaz-Mesa, Vanesa
    Cuadrado, Alberto Villarrubia
    Elordi, Enrique Artiaga
    Poves, Jose Manuel Larrosa
    Blasco, Alejandro
    Mateo, Antonio
    Civiale, Claudine
    Bonino, Laura
    Cano-Ortiz, Antonio
    OPHTHALMOLOGY AND THERAPY, 2025, : 675 - 692
  • [25] Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition
    Shigeyasu, Chika
    Yamada, Masakazu
    Akune, Yoko
    Tsubota, Kazuo
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2015, 59 (06) : 415 - 420
  • [26] Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition
    Chika Shigeyasu
    Masakazu Yamada
    Yoko Akune
    Kazuo Tsubota
    Japanese Journal of Ophthalmology, 2015, 59 : 415 - 420
  • [27] Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
    Rajpal, Rajesh K.
    Ross, Bryan
    Rajpal, Sachin D.
    Khoa Hoang
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 925 - 931
  • [28] Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program
    Chan, Clara C.
    Prokopich, C. Lisa
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2019, 22 : 49 - 56
  • [29] EFFICACY OF 2% REBAMIPIDE OPHTHALMIC SOLUTION IN THE TREATMENT OF DRY EYES
    Patkar, Priyanka
    Shrivastava, Saurabh
    Ramakrishnan, Reshma
    Warade, Sonali
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 : 84 - 84
  • [30] In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
    Cockrum, Paul
    Justice, Angela
    Jasek, Mark C.
    Sheppard, John D.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)